Skip to main content
. 2022 Jul 27;32:100823. doi: 10.1016/j.neo.2022.100823

Figure 5.

Figure 5

Oral administration of SOMCL-19-133 suppresses the growth of RKO and MV-4-11 xenografts in nude mice. (a and b) The effects of oral administration of SOMCL-19-133 on (a) human colon cancer RKO and (b) human leukemia MV-4-11 xenografts. Mice bearing subcutaneous xenografts were dosed with SOMCL-19-133 orally daily, or MLN4924 (120 mg/kg; i.v.) twice a week for (a) 21 days or (b) 18 days (n = 6). The tail indicated the tumor disappeared in that mouse.